Sanchez-Diener, IZamorano, LPeña, COcampo-Sosa, ACabot, GGomez-Zorrilla, SAlmirante, BAguilar, MGranados, ACalbo, ERodriguez-Baño, JRodriguez-Lopez, FTubau, FMartinez-Martinez, LNavas, AOliver, A2023-01-252023-01-252019-06-27Sánchez-Diener I, Zamorano L, Peña C, Ocampo-Sosa A, Cabot G, Gómez-Zorrilla S, et al. Weighting the impact of virulence on the outcome of Pseudomonas aeruginosa bloodstream infections. Clin Microbiol Infect. 2020 Mar;26(3):351-357http://hdl.handle.net/10668/14230We assessed the association between the lethality of Pseudomonas aeruginosa in a Caenorhabditis elegans model and outcomes of P. aeruginosa bloodstream infections. A total of 593 P. aeruginosa bloodstream isolates recovered from a prospective Spanish multicentre study were analysed. Clinical variables, susceptibility profiles and Type III Secretion System (TTSS) genotypes (exoU/exoS genes) were available from previous studies. A C. elegans virulence score (CEVS) was used, classifying the isolates into high (CEVS 4-5), intermediate (CEVS 3) and low (CEVS 1-2) virulence. The main outcome analysed was 30-day mortality. Up to 75% (446/593) of the isolates showed a high-virulence phenotype, and 17% (101/593) a low-virulence one. No association between virulence phenotype and the main outcome variable (30-day mortality) was found (29/101 (28.7%) versus 127/446 (28.5%), p 1). However, an inverse association between C. elegans virulence and multidrug-resistant and extensively drug-resistant profiles was documented (OR 0.655 (95% CI 0.571-0.751) and OR 0.523 (95% CI 0.436-0.627), p Our results indicate that the P. aeruginosa virulence phenotype in a C. elegans model correlates with virulence genotype (TTSS) and resistance profile, but it is a poor prognostic marker of mortality in bloodstream infections.enBloodstream infectionsCaenorhabditis elegansPseudomonas aeruginosaVirulenceAgedAged, 80 and overAnti-Bacterial AgentsBacteremiaBacterial ProteinsBacterial Secretion SystemsDrug Resistance, BacterialFemaleGenotypeHumansMaleMicrobial Sensitivity TestsMiddle AgedPatient Outcome AssessmentPhenotypePseudomonas InfectionsPseudomonas aeruginosaPublic Health SurveillanceVirulenceVirulence Factorsresearch article31288102open accessAntibacterianosBacteriemiaFactores de virulenciaFarmacorresistencia bacterianaFenotipoGenotipoInfecciones por Pseudomonas10.1016/j.cmi.2019.06.0341469-0691http://www.clinicalmicrobiologyandinfection.com/article/S1198743X19303891/pdf